TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases
TYK Medicines, Inc. (HKG: 2410) announced that its Category 1 drug asandeutertinib (TY‑9591), a third‑generation EGFR...
HKG: 2410
TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 26, 2025, that it has entered...
TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 14, 2025, that the results of...
TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis
China-based TYK Medicines, Inc. (HKG: 2410) announced the formal submission of a pre-NDA communication package...
TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...